Literature DB >> 12923446

Interleukin-9 promotes eosinophilic rejection of mouse heart allografts.

Lionel F Poulin1, Mélisande Richard, Alain Le Moine, Robert Kiss, Andrew N McKenzie, Michel Goldman, Jean-Christophe Renauld, Jacques Van Snick, Michel Y Braun.   

Abstract

BACKGROUND: Eosinophils participate in allograft rejection when donor-reactive helper T lymphocytes are T-helper type 2 (Th2)-biased. Whereas the involvement of interleukin (IL)-4 and IL-5 in these forms of rejection is well established, the role of IL-9, another Th2-type cytokine promoting eosinophilia, has not been determined.
METHODS: We first used real-time polymerase chain reaction to quantify IL-9 mRNA in rejected allografts in a mouse model of fully mismatched heart transplantation in which recipients were devoid of CD8 T cells and developed a Th2 alloimmune response. We then compared allograft survival in wild-type versus IL-9-deficient mice depleted of CD8 T cells. Finally, we compared the fate of major histocompatibility complex class II-mismatched cardiac transplants from wild-type versus IL-9 transgenic donors to determine the influence of IL-9 overexpression within the graft.
RESULTS: The Th2 alloimmune response in CD8-deficient mice was associated with the accumulation of IL-9 mRNA in the rejected graft. In IL-9-deficient recipients depleted of CD8 T cells, eosinophil infiltration of heart allografts did not develop, but rejection still occurred. In the major histocompatibility complex class II disparate model, heart allografts from IL-9 transgenic donors were acutely rejected, whereas grafts from wild-type donors did not develop rejection. Acute rejection of IL-9 transgenic hearts was associated with massive eosinophil infiltration and prevented by neutralization of either IL-4 or IL-5.
CONCLUSION: IL-9 is critically involved in heart transplant eosinophilia in conjunction with IL-4 and IL-5.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923446     DOI: 10.1097/01.TP.0000071201.32424.D2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Knockout of MicroRNA-155 Ameliorates the Th17/Th9 Immune Response and Promotes Wound Healing.

Authors:  Chen-Rong Wang; Hong-Fei Zhu; Yong Zhu
Journal:  Curr Med Sci       Date:  2019-12-16

2.  Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation.

Authors:  Nannan Pang; Jianli Xu; Jianhua Qu; Xianlin Duan; Hailong Yuan; Gang Chen; Ming Jiang; Jianbing Ding
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

3.  Interleukin-9 release from human kidney grafts and its potential protective role in renal ischemia/reperfusion injury.

Authors:  Kirsten A Kortekaas; Dorottya K de Vries; Marlies E J Reinders; Ellen Lievers; Jan Ringers; Jan H N Lindeman; Alexander F M Schaapherder
Journal:  Inflamm Res       Date:  2012-09-13       Impact factor: 4.575

Review 4.  IL-9: basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity.

Authors:  Hongmei Li; Abdolmohamad Rostami
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-18       Impact factor: 4.147

Review 5.  Rejection and regulation: a tight balance.

Authors:  Isa F Ashoor; Nader Najafian
Journal:  Curr Opin Organ Transplant       Date:  2012-02       Impact factor: 2.640

6.  A modified method for heterotopic mouse heart transplantion.

Authors:  Chuanmin Wang; Zane Wang; Richard Allen; G Alex Bishop; Alexandra F Sharland
Journal:  J Vis Exp       Date:  2014-06-23       Impact factor: 1.355

Review 7.  The unique features of Th9 cells and their products.

Authors:  Cuiyan Tan; Igal Gery
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

8.  Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis.

Authors:  Ida Gregersen; Mona Skjelland; Sverre Holm; Kirsten B Holven; Kirsten Krogh-Sørensen; David Russell; Erik T Askevold; Christen P Dahl; Stein Ørn; Lars Gullestad; Tom E Mollnes; Thor Ueland; Pål Aukrust; Bente Halvorsen
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

9.  Rapamycin resistant murine th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity.

Authors:  Courtney W Mangus; Paul R Massey; Daniel H Fowler; Shoba Amarnath
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

10.  Innate immunity and resistance to tolerogenesis in allotransplantation.

Authors:  Gilles Benichou; Makoto Tonsho; Georges Tocco; Ognjenka Nadazdin; Joren C Madsen
Journal:  Front Immunol       Date:  2012-04-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.